首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation.
【24h】

Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation.

机译:用纯化的天然和重组变应原免疫可诱导小鼠IgG1抗体,该抗体识别与人IgE类似的表位,并抑制人IgE-变应原相互作用和变应原诱导的嗜碱性粒细胞脱粒。

获取原文
获取原文并翻译 | 示例
           

摘要

Molecular characterization of allergens by recombinant DNA technology has made rapid progress in the recent few years. In the present study we immunized mice with aluminum hydroxide-adsorbed purified recombinant major timothy grass pollen allergens (rPhl p 1, rPhl p 2, rPhl p 5), dog albumin, a major animal dander allergen, and proteins with low (beta-lactoglobulin) or no (ribulose diphosphate carboxylase) allergenic potential in humans. Allergens that bind high levels of IgE in humans (Phl p 1, Phl p 5, dog albumin) induced high IgE and IgG1 levels in mice, whereas proteins with little or no allergenic activity in humans failed to induce significant IgE and IgG1 levels in mice. Continuous immunization for a period of 27 wk resulted in the production of mouse IgG1 Abs that recognized recombinant allergen fragments/epitopes defined by IgE Abs of allergic patients. As a consequence, allergen-specific mouse Abs strongly inhibited human IgE binding to the allergens and suppressed the allergen-induced histamine release from human basophils. In summary, our data indicate that 1) the allergenic potency of a protein may be related to its overall immunogenicity and 2) prolonged immunization with single purified recombinant allergens induces protective IgG Abs. The presented experimental in vivo/in vitro system allows the evaluation of Ag preparations (e.g., recombinant allergens) to be used for immunotherapy in humans.
机译:近年来,通过重组DNA技术对过敏原进行分子表征已经取得了飞速进展。在本研究中,我们用氢氧化铝吸附的纯化的重组主要提摩西草花粉过敏原(rPhl p 1,rPhl p 2,rPhl p 5),狗白蛋白,主要动物皮屑过敏原和低蛋白(β-乳球蛋白)免疫小鼠)或对人类没有(核糖二磷酸羧化酶)过敏原潜能。结合人类高水平IgE的变应原(Phl p 1,Phl p 5,狗白蛋白)在小鼠中诱导高IgE和IgG1水平,而在人类中几乎没有或没有变应原活性的蛋白质未能在小鼠中诱导显着的IgE和IgG1水平。连续免疫27周后,小鼠IgG1 Abs产生,该抗体识别由过敏患者的IgE Abs定义的重组变应原片段/表位。结果,变应原特异性小鼠Abs强烈抑制人IgE与变应原的结合,并抑制了变应原诱导的从人嗜碱性粒细胞释放的组胺。总而言之,我们的数据表明1)蛋白质的变应原效力可能与其整体免疫原性有关,以及2)单一纯化的重组变应原延长的免疫诱导了保护性IgG Abs。提出的体内/体外实验系统允许评估用于人类免疫治疗的银制剂(例如重组变应原)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号